NCT05985018

Brief Summary

Irritable bowel syndrome (IBS) affects 5-10% of the population, and incurs substantial health impairment and healthcare utilization. Over 80% of individuals with IBS report food to trigger or aggravate symptoms, with many seeking to undertake dietary modifications. Current guidelines recommend first-line therapy with the relatively straightforward traditional dietary advice, with the more complex and restrictive low FODMAP diet reserved as second-line therapy. There is emerging data suggesting that the Mediterranean diet may also improve the symptoms of IBS, although it has not yet been subject to any head-to-head randomized dietary trials to help position it within the treatment algorithm. Given the relative ease of implementing the Mediterranean diet, alongside its recognized cardio-metabolic and mental health benefits, studying its efficacy in IBS is attractive as it could potentially pave the way for another first-line dietary option being available to patients before escalating to the demanding and resource intensive second-line therapies. The investigators will perform a randomized trial comparing the clinical efficacy of traditional dietary advice vs. a Mediterranean diet in IBS. Following dietary randomization, participants will complete validated questionnaires to assess changes in IBS symptoms, quality of life, mood, somatic symptoms, nutritional status, as well as dietary satisfaction and adherence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
139

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 9, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

September 30, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2024

Completed
Last Updated

March 14, 2025

Status Verified

March 1, 2025

Enrollment Period

1.2 years

First QC Date

July 25, 2023

Last Update Submit

March 11, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of IBS patients experiencing clinical response with traditional dietary advice vs. Mediterranean diet

    IBS symptom severity scale (IBS-SSS) where a 50-point reduction denotes a meaningful clinical response

    Baseline to Week 6

Secondary Outcomes (7)

  • Changes in individual items of the IBS-SSS

    Baseline to Week 6

  • Changes in Anxiety and Depression

    Baseline to Week 6

  • Changes in Somatic Symptom reporting

    Baseline to Week 6

  • Changes in quality of life

    Baseline to Week 6

  • Dietary satisfaction to assigned intervention

    Week 6

  • +2 more secondary outcomes

Study Arms (2)

Traditional Dietary Advice

ACTIVE COMPARATOR

Its main elements are to adopt sensible eating habits and avoid excess fatty foods, spicy foods, processed foods, caffeine, fizzy drinks and alcohol.

Other: Traditional Diet

Mediterranean Diet

ACTIVE COMPARATOR

The principle components is a diet rich in vegetables, pulses, whole grains, and olive oil

Other: Mediterranean Diet

Interventions

Provided as an educational leaflet

Traditional Dietary Advice

Provided as an educational leaflet

Mediterranean Diet

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • IBS Symptom Severity Scale(IBS-SSS) \> 75
  • Online access
  • English literate

You may not qualify if:

  • Organic gastrointestinal diseases (e.g. inflammatory bowel disease, GI cancer, coeliac disease, microscopic colitis, bile acid diarrhoea)
  • Major abdominal surgery (except laparoscopy, appendectomy, cholecystectomy)
  • History of eating disorder
  • Body mass index \<20
  • Current dietary interventions
  • Current use of opioids/antibiotics
  • Titrating dose of neuromodulators
  • Severe systemic disease (e.g. cardiac, renal, respiratory, psychiatric) necessitating frequent medical consultations/hospitilisations
  • Pregnant
  • Diabetes mellitus
  • Scleroderma
  • Memory impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Hallamshire Hospital

Sheffield, South Yorkshire, S10 2JF, United Kingdom

Location

Related Publications (1)

  • Bamidele JO, Brownlow GM, Flack RM, Buckle RL, Shaw CC, Shiha MG, Aziz I. The Mediterranean Diet for Irritable Bowel Syndrome : A Randomized Clinical Trial. Ann Intern Med. 2025 Dec;178(12):1709-1717. doi: 10.7326/ANNALS-25-01519. Epub 2025 Oct 28.

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

Diet, Mediterranean

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Diet, Plant-BasedDiet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Imran Aziz

    Sheffield Teaching Hospitals NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2023

First Posted

August 9, 2023

Study Start

September 30, 2023

Primary Completion

December 20, 2024

Study Completion

December 20, 2024

Last Updated

March 14, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations